(12) United States Patent
`US 8,304,405 B2
`(10) Patent No.:
`Lulla et al.
`(45) Date of Patent:
`*Nov. 6, 2012
`
`US008304405B2
`
`(54) COMBINATION OF AZELASTINE AND
`CICLESONIDE FOR NASAL
`ADMINISTRATION
`
`(75)
`
`Inventors: Amar Lulla, Mumbai (IN); Geena
`Malhotra, Mumbai (IN)
`
`(73) Assignee: Cipla Limited, Mumbai (IN)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21) Appl. No.: 12/508,393
`
`(22)
`
`(65)
`
`Filed:
`
`Jul. 23, 2009
`
`Prior Publication Data
`
`US 2009/0318397 A1
`
`Dec. 24, 2009
`
`Related US. Application Data
`
`filed as
`(62) Division of application No. 10/518,016,
`application No. PCT/GB03/02557 on Jun. 13, 2003,
`now Pat. No. 8,168,620.
`
`(30)
`
`Foreign Application Priority Data
`
`Jun. 14, 2002
`
`(GB) ................................... 02137396
`
`(51)
`
`Int. Cl.
`(2006.01)
`A01N 45/00
`(52) US. Cl.
`....................................................... 514/171
`(58) Field of Classification Search ........................ None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`2,837,464 A
`3,067,197 A
`3,312,590 A
`3,506,694 A
`3,557,162 A
`3,639,434 A
`3,755,302 A
`3,828,080 A
`3,856,828 A
`3,891,631 A
`3,981,894 A
`3,989,686 A
`4,093,721 A
`4,113,680 A
`4,187,301 A
`4,188,385 A
`4,198,403 A
`4,221,787 A
`4,261,984 A
`4,263,289 A
`4,267,173 A
`4,285,937 A
`4,310,466 A
`4,335,121 A
`4,377,575 A
`4,472,393 A
`4,607,028 A
`4,710,495 A
`4,861,765 A
`4,992,474 A
`4,994,439 A
`A
`4,996,335
`
`6/1958 Nobile
`12/1962 Agnello et a1.
`4/1967 Elks et a1.
`4/1970 Oxley
`1/1971 Voorschoten et a1.
`2/1972 Oxley et a1.
`8/1973 Ercoliet a1.
`8/1974 Mayet a1.
`12/1974 Phillipps et a1.
`6/1975 Phillipps et a1.
`9/1976 Phillipps et a1.
`11/1976 Phillipps et a1.
`6/1978 Phillipps et a1.
`9/1978 Kamano et a1.
`2/1980 Edwards
`2/1980 Edwards
`4/1980 Alvarez
`9/1980 Bodor et a1.
`4/1981 Alvarez
`4/1981 Edwards
`5/1981 Draper
`8/1981 Kalvoda
`1/1982 Edwards
`6/1982 Phillipps et a1.
`3/1983 Stache etal.
`9/1984 Shapiro
`8/1986 Schmidlin
`12/1987 Bodor
`8/1989 Mitsukuchiet a1.
`2/1991 Skidmore etal.
`2/1991 Longnecker et al.
`2/1991 Bodor
`
`16 Claims, No Drawings
`
`000001
`
`5,063,222 A
`5,081,113 A
`5,086,050 A
`5,164,194 A
`5,202,316 A
`5,232,919 A
`5,271,946 A
`5,362,721 A
`5,420,120 A
`5,608,093 A
`5,658,549 A
`5,658,919 A
`5,707,984 A
`5,837,699 A
`5,849,265 A
`5,889,015 A
`5,914,122 A
`5,972,920 A
`5,981,517 A
`6,017,963 A
`6,057,307 A
`6,127,353 A
`6,136,294 A
`B
`6,197,761
`
`1
`
`11/1991 Komoto et a1.
`1/1992 Claussner et a1.
`2/1992 Hettche et a1.
`11/1992 Hettche
`4/1993 Claussner et a1.
`8/1993 Schefller et a1.
`12/1993 Hettche
`11/1994 Stache et a1.
`5/1995 Boltralik
`3/1997 Stache et a1.
`8/1997 Akehurst et a1.
`8/1997 Ratnaraj et a1.
`1/1998 Tjoeng et a1.
`11/1998 Sequeira et a1.
`12/1998 Li-Bovet et a1.
`3/1999 Sequeira et a1.
`6/1999 Otterbeck et a1.
`10/1999 Seidel
`11/1999 Bodor
`1/2000 Alfonso et a1.
`5/2000 Sequeira et a1.
`10/2000 Yuen et a1.
`10/2000 Adjei et a1.
`3/2001 Biggadike et a1.
`(Continued)
`
`AU
`
`FOREIGN PATENT DOCUMENTS
`2003244799 B2
`l2/2003
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`Schmidt et a1., The new topical steroid ciclesonide is effective in the
`treatment of allergic rhinitis, Journal of Clinical Pharmacology, v01.
`39, N0. 10, pp. 1062-1069, 1999*
`Applicants response to foreign communicati0n7EP 037382801,
`May 22, 2006, 36 pages.
`Applicants response to foreign communicati0n7EP 037382801,
`Jan. 18, 2008, 14 pages.
`Busse, W. W., et a1., “Corticosteroid-sparing effect ofazelastine in the
`management of bronchial asthma,” American Journal of Respiratory
`and Critical Care Medicine, 1996, pp. 122-127, vol. 153, N0. 1,
`American Lung Association, New York, NY, XP-000604179
`Foreign communication from the priority applicati0n7Search
`Report, GB 02137396, Nov. 22, 2002, 4 pages.
`Foreign communication from the priority applicati0n7Internati0na1
`Search Report, PCT/GB03/02557, Sep. 17, 2003, 3 pages.
`
`(Continued)
`
`Primary Examiner 7 James H. Alstrum-Acevedo
`Assistant Examiner 7 Thor Nielsen
`
`(74) Attorney, Agent, or Firm 7 Conley Rose, P.C.; Rodney
`B. Carroll
`
`(57)
`
`ABSTRACT
`
`A pharmaceutical product or formulation, which comprises
`azelastine or a pharmaceutically acceptable salt, solvate or
`physiologically functional derivative thereof, and a steroid, or
`a pharmaceutical acceptable salt, solvate or physiologically
`functional derivative thereof, preferably the product or for-
`mulation being in a form suitable for nasal or ocular admin-
`istration.
`
`Exhibit 1 167
`
`Exhibit 1167
`IPR2017-00807
`ARGENTUM
`
`IPR2017-00807
`
`ARGENTUM
`
`000001
`
`

`

`US 8,304,405 B2
`
`Page2
`
`U.S. PATENT DOCUMENTS
`
`6,261,539 B1
`6,294,153 B1
`6,319,513 B1
`6,330,938 B1
`6,391,340 B1
`6,395,300 B1
`6,416,743 B1
`6,525,228 B2
`6,537,983 B1
`6,583,180 B2
`6,787,532 B2
`6,921,757 B2
`7,101,866 B2
`7,244,742 B2
`7,776,315 B2
`2002/0061281 A1
`2002/0076382 A1
`2002/0081266 A1
`2002/0103392 A1
`2002/0165211 A1
`2002/0173496 A1
`2002/0177581 A1
`2003/0018019 A1
`2003/0073676 A1
`2003/0109511 A1
`2003/0144257 A1
`2003/0158163 A1
`2004/0053904 A1
`2004/0136918 A1*
`
`7/2001 Adjeietal.
`9/2001 Modi
`11/2001 Dobrozsi
`12/2001 Herve etal.
`5/2002 MalmqVist-Granlund et al.
`5/2002 Straub etal.
`7/2002 Fassberg et al.
`2/2003 ChauVin et al.
`3/2003 Biggadike et al.
`6/2003 Linketal.
`9/2004 Biggadike et al.
`7/2005 Cuenoud et al.
`9/2006 Biggadike et al.
`7/2007 Pieperetal.
`8/2010 Pairet et a1.
`5/2002 Osbakken et a1.
`6/2002 Kaplan et a1.
`6/2002 Woolfe et a1.
`8/2002 Stache et a1.
`11/2002 Biggadike et a1.
`11/2002 Biggadike
`11/2002 Biggadike
`1/2003 Meade et a1.
`4/2003 Biggadike et a1.
`6/2003 Biggadike et a1.
`7/2003 Biggadike et a1.
`8/2003 Cuenoudet a1.
`3/2004 Komoto etal.
`7/2004 Garrett et a1.
`
`................... 424/46
`
`WO
`
`$8
`W0
`W0
`W0
`WO
`W0
`WO
`WO
`WO
`W0
`WO
`WO
`WO
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`WO
`W0
`WO
`W0
`W0
`W0
`W0
`W0
`W0
`$8
`WO
`88
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`ZA
`
`9619199
`
`3:33;; A1
`9705136
`9715298
`9721721
`9721724
`9724365
`9740836
`9746243 A1
`9817676
`9834596
`9848839 Al
`9901467
`9925359
`9932089
`0016814
`0033892
`0038811
`0048587
`0049993
`0066522
`0104118
`0120331
`0154481
`0154664
`0157025
`0162722
`0178736
`0178739
`0178741
`
`0200199
`0200679
`0202565
`0207767
`0208243
`0211711 A2
`0212265
`0212266
`0213868
`82323:
`02051422
`85322132
`02070490
`02076933
`02085296
`02088167
`02100879
`03000241
`03013427
`03033000
`03035668
`03040691
`03042229
`03042230
`03048181
`03062259
`03064445
`03066033
`03066036
`03066656
`03072592
`03086399
`03105856 A1
`2004013156
`2004019955 A1
`2008012338 A2
`872389
`
`6/1996
`
`“mag?
`2/1997
`5,1997
`6/1997
`6/1997
`7,1997
`“/1997
`12/1997
`4/l998
`8,1998
`ll/l998
`“1999
`5/1999
`7/1999
`”000
`6,2000
`7,2000
`8/2000
`8,2000
`“/2000
`1 /2001
`”001
`8,2001
`8/2001
`8/2001
`8,2001
`10,2001
`10/2001
`10,2001
`
`1/2002
`1/2002
`1/2002
`1/2002
`1/2002
`2/2002
`2/2002
`2/2002
`2/2002
`451/3883
`7/2002
`0538
`9/2002
`10/2002
`10/2002
`11,2002
`”/2002
`“2003
`2/2003
`4/2003
`5/2003
`5/2003
`5/2003
`5/2003
`6/2003
`7,2003
`8/2003
`8/2003
`8/2003
`8/2003
`9/2003
`10/2003
`12/2003
`2/2004
`3/2004
`1/2008
`4/1987
`
`OTHER PUBLICATIONS
`Foreign communication from the priority applicationilnternational
`Preliminary Examination Report, PCT/GB03/02557, Aug. 26, 2004,
`6 Pages.
`Foreign communication from a related counterpart applicationi
`Examination Report, EP Application 03738280.l, Nov. 10, 2005, 4
`pages.
`
`000002
`
`11/2004 Weinrich et al.
`2004/0235807 A1
`l2/2004 Yann1etal.
`2004/0242638 A1
`7/2005 Miyadia et al.
`2005/0163724 A1
`9/2005 Jost-Price et a1.
`2005/0192261 A1
`2/2006 Lulla et a1.
`2006/0025391 A1
`5/2006 Dang et a1.
`2006/0110331 A1
`10/2006 Lane
`2006/0228306 A1
`1/2007 Dang et a1.
`2007/0020330 A1
`11/2009 Myles et a1.
`2009/0286762 A1
`6/2010 Fuge et a1.
`2010/0152147 A1
`FOREIGN PATENT DOCUMENTS
`A
`
`BE
`DE
`DE
`DE
`DE
`DE
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`1L
`JP
`JP
`JP
`$50
`WO
`W0
`W0
`WO
`W0
`
`1059906
`2164058 A1
`3836579 A1
`19947234 A1
`10152369 A1
`0004773
`0057401
`0179583
`0393658
`0416951
`0780127
`0780127 A1
`1519731 B1
`2072051 A1
`1191965
`1296458
`1384372
`1438940
`1517278
`2079755
`2088877
`2140800
`2389530 A
`109656
`04208267
`8291072
`8291073
`ZOOZéggiggg A1
`8903390
`9015816
`9104252
`9214472
`9531964
`
`“959
`7/1972
`5/1989
`9/1999
`5/2002
`10/1979
`8/1982
`4/ 1986
`10/1990
`“991
`“997
`6/1997
`4/2009
`6/2009
`5/1970
`11/1972
`”975
`“976
`”978
`“1982
`“982
`1241984
`12 2003
`”998
`7/1992
`11/1996
`11,1996
`léfiggg
`4/ 1989
`12/1990
`4/1991
`9/l992
`11/1995
`
`000002
`
`

`

`US 8,304,405 B2
`Page3
`
`Foreign communication from a related counterpart applicationi
`Examination Report, EP Application 03738280.1, Jul. 18, 2007, 5
`pages.
`May, Percy, et al., “May’s Chemistry of Synthetic Drugs,” Fifth
`Edition, 1964, pp. 12-17, Longmans.
`Patent application entitled “Combination of azelastine and steroids,”
`byAmarLulla, etal., filedJul. 23, 2009 asU.S.Appl.No. 12/508,388.
`Portman, D. et al., Acceptability of local treatment of allergic rhinitis
`with a combination of a corticoid (beclomethasone) and an
`antihistaminic (azelastine), Database Medline, 2000, vol. 121, No.4,
`pp. 273-279, XP-002252974.
`Office Action dated Jan. 23, 2009, (27 pages), U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`ABPI Compendium of Data Sheets and Summaries of Product Char-
`acteristics, 1999-2000, Cover page, p. 43 and Index p. 1882,
`Datapharm Publications Limited, London, Great Britain.
`Dykewicz, Mark S., et al., “Diagnosis and Management of Rhinitis:
`Complete Guidelines of the Joint Task Force on Practice Parameters
`in Allergy, Asthma and Immunology,” Annals of Allergy, Asthma, &
`Immunology, vol. 81, Nov. (Part II) 1998, pp. 478-518.
`Foreign communication from a related counterpart applicationi
`Notice ofOpposition, EP Application 03738280.1, Feb. 22, 2010, 22
`pages.
`Office Action (Final) dated Apr. 28, 2010, (29 pages), U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Preservative, definition of. Composite definition of preservative in
`the Medical dictionary, from intemet site http://medical-dictionary.
`thefreedictionary.com/preservative, dated Nov. 4, 2009, 3 pages.
`Herrero, Vanrell, R., “Preservatives in Ophthalmic Formulations: An
`Overview,” Arch. Soc. Esp. Oftalmol, 2007, vol. 82., pp. 531-532.
`Hodges, Norman, et al., “Antimicrobial Preservative Efficacy Test-
`ing,” Handbook of Microbiological Quality Control, Pharmaceuti-
`cals and Medical Devices, 2000, p. 168 Plus cover page and publi-
`cation page, Taylor & Francis Publisher, USA and Canada.
`Johnson, Malcom, “Development of fluticasone propionate and com-
`parison with other
`inhaled corticosteroids,” J. Allergy Clin.
`Immunol., Apr. 1998, vol. 101, No.4, Part 2, pp. S434-S439.
`Patent Application entitled “Combination of Azelastine and
`Steriods,” by Amar Lulla, et al., filed Sep. 10, 2010 as US. Appl. No.
`12/879, 5 1 5 .
`Office Action dated Sep. 30, 2010, US. Appl. No. 12/508,388, filed
`Jul. 23, 2009, 22 pages.
`Product Information, Nasonex®, Aug. 2001, 22 pages, Schering
`Corporation, Kenilworth, NJ, US.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Ratner, Paul H., et al., “Combination therapy with azelastine hydro-
`chloride nasal spray and fluticasone propionate nasal spray in the
`treatment of patients with seasonal allergic rhinitis,” Annals of
`Allergy, Asthma & Immunology, Jan. 2008, vol. 100, Cover page,
`publishing page, pp. 74-81.
`Ratner, Paul H., et al., “A Comparison of the Efficacy of Fluticasone
`Propionate Aqueous Nasal Spray and Loratadine, Alone and in Com-
`bination, for the Treatment of Seasonal Allergic Rhinitis,” The Jour-
`nal of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125,
`Appleton & Lange.
`Reddy, Indra K., ed., “Ocular Therapeutics and Drug Delivery: A
`Multi-Disciplinary Approach,” 1996, pp. 382-385 plus cover page
`and publication page, Technomic Publishing Company, Inc.
`Safety Data Sheet, SDS No. 110556, Jul. 4, 2008, V14, Flonase Nasal
`Spray, 5 pages, GlaxoSmithKline.
`Safety Data Sheet, SDS No. 110536, Jun. 23, 2008, V13, Beconase
`Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.
`Salib Rami Jean, et al., “Safety and Tolerability Profiles of Intranasal
`Antihistamines and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety 2003, vol. 26, No. 12, Cover page,
`publication page, pp. 863-893, ADIS Data Information BV.
`Simpson, Richard J., “Budesonide and terfenadine, separately and in
`combination, in the treatment of hay fever,” Annals of Allergy, Dec.
`1994, vol. 73, Cover page, publication page, pp. 497-502.
`
`Spector, Sheldon, “Ideal pharmacotherapy for allergic rhinitis,” J
`Allergy Clin Immunol, 1999, vol. 103, No. 3, Part 2, pp. S386-S387,
`Mosby, Inc.
`Wang, De-Yun, “Treatment of Allergic Rhinitis: H1-Antihistamines
`and Intranasal Steroids,” Current Drug TargetsiInflammation &
`Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
`Wiseman, Lynda R., et al., “Intranasal Fluticasone Propionate: A
`Reappraisal of its Pharmacology and Clinical Efficacy in the Treat-
`ment of Rhinitis,” Drugs, 1997, vol. 53, No. 5, pp. 885-907, Adis
`International Limited.
`1 Interna-
`World Review 2001: The Pharmaceutical Market, vol.
`tional, IMS Health, 2001, cover, preface, and copyright pages plus
`pp. 4-42 and 5-1 through 5-11, IMS A.G.
`Applicant Response to foreign communication EP Patent 1519731,
`Aug. 11, 2011, 252 pages.
`ABPI Data Sheet Compendium, 1995-96, cover page plus pp. 38-39,
`Datapharm Publications Limited, London, Great Britain.
`Akerlund, Anders, et al., “Clinical trial design, nasal allergen chal-
`lenge models, and considerations of relevance to pediatrics, nasal
`polyposis, and different classes of medication,” J. Allergy Clin.
`Immunol., Mar. 2005, vol. 115, No. 3, pp. S460-S482.
`Applicants
`response to foreign communicationiKR10-2004-
`7020819, Dec. 27, 2010, 18 pages.
`Applicants response to foreign communicationiEP 03738280.1
`(EP Patent 1519731) , Sep. 6,2010, 15 pages.
`Applicants response to foreign communication%A 2489427, Dec.
`20, 2010, 10 pages.
`Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcel-
`lulose Sodium, NF Dispersible Cellulose, BP, Specifications and
`Analytical Methods, RC-16 Updated Oct. 1995 (Feb. 1999), 6 pages,
`FMC BioPolymer.
`Opposition to EP 1518731, Aug. 8, 2011, 19 pages.
`Aurora, Jack, “Nasal Delivery; Development of Nasal Delivery Sys-
`tems: A Review,” Drug Delivery Technology, vol. 2, No. 7, Oct. 2002,
`8
`pages,
`http://www.drugdeliverytech.com/ME2/Segments/
`Publications:Article
`&id:9EB19EB2F29F462089CE081473F5F3CA.
`Baena-Cagnani, Carlos E ., “Safety and Tolerability ofTreatments for
`Allergic Rhinitis in Children,” Drug Safety 2004, vol. 27, No. 12, pp.
`883-898, ADIS Data Information BV.
`Barnes, M. L., et al., “Effects of levocetirizine as add-on therapy to
`fluticasone in seasonal allergic rhinitis,” Clinical and Experimental
`Allergy, Jan. 27, 2006, vol. 36, pp. 676-684, Blackwell Publishing
`Ltd.
`Berge, Stephen M., et al., “Pharmaceutical Salts,” Journal of Phar-
`maceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
`Block, John H., et al., “Inorganic Medicinal and Pharmaceutical
`Chemistry,” 1986, cover, publication, and preface pages plus p. 100,
`Indian Edition, Varghese Publishing House, Bombay, India.
`Cipla Sixty-Ninth Annual Report 2004-2005, cover pages, informa-
`tion page, plus pp. 3, 5, and 44.
`Di Lorenzo, G., et al., “Randomized Placebo-controlled Trial Com-
`paring fluticasone aqueous nasal spray in mono-therapy, fluticasone
`plus cetirizine, fluticasone plus montelukast and cetirizine plus
`montelukast for seasonal allergic rhinitis,” Clin. Exp. Allergy, 2004,
`vol. 34, pp. 259-267., Blackwell Publishing Ltd.
`Duonase Data Sheet, “The Complete Rhinitis Control,” 6 pages,
`Cipla Limited, Mumbai, India, 1900.
`Drouin, Michel A., et al., “Adding Loratadine to Topical Nasal Ste-
`roid Therapy Improves Moderately Severe Seasonal Allergic
`Rhinoconjunctivitis,”Advances in Therapy, vol. 12, No. 6, Nov/Dec.
`1995, pp. 340-349, Health Communications Inc.
`File history ofAustralian Patent Application No. AU2003244799, 38
`pages, 1900.
`File history of Brazilian Patent Application No. PI 0312128-3, 27
`pages, 1900.
`File history of Canadian Patent Application No. 2,489,427, 19 pages,
`1900.
`File history of Korean Patent Application No. 10-2004-7020819, 89
`pages.
`File history of Mexican Patent Application No. PNa/2004/01266
`(now Patent No. 265349), 86 pages.
`
`000003
`
`000003
`
`

`

`US 8,304,405 B2
`
`Page4
`
`File history of Polish Patent Application No. P-373001, 95 pages,
`1900.
`File history of Russian Patent Application No. RU 2361593 C2, 65
`pages, 1900.
`File history of South African Patent Application No. 2005/0331 (now
`Patent No. 2005/0331), 18 pages.
`Foreign communication from a related counterpart applicationi
`CA2,489,427, Examination Report, Jun. 18, 2010, 3 pages.
`Foreign communication from a related counterpart applicationi
`CA2,489,427, Examination Report, Mar. 24, 2011, 2 pages.
`Foreign communication from a related counterpart applicationiEP
`Application 03738280.1, Examination Report, Nov. 10, 2005, 4
`pages.
`Foreign communication from a related counterpart applicationiEP
`Application 0373 8280. 1, Examination Report, Jul. 18, 2007, 5 pages.
`Foreign communication from a related counterpart applicationiEP
`Application 03738280.1, Notice of Intent to Grant, Oct. 23, 2008, 6
`pages.
`Foreign communication from a related counterpart applicationi
`Summons to Attend Oral Proceedings, EP Application 03738280.1,
`Feb. 8, 2011, 1 page.
`Foreign communication from a related counterpart applicationi
`AU2003244799, Examination Report, Nov. 20, 2007, 2 pages.
`Foreign communication from a related counterpart applicationiKR
`10-2004-7020819, Examination Report, Aug. 26, 2010, 8 pages.
`Foreign communication from a related counterpart applicationi
`Examination Report, RU 2005100781, Apr. 23, 2007, 6 pages.
`Foreign communication from a related counterpart applicationi
`Examination Report, RU 2005100781, May 23, 2008, 3 pages.
`Foreign communication from a related counterpart applicationi
`Translation of Office Action, Israel Patent Application 165771, Jul.
`11, 2011, 3 pages.
`Galant, Stanley P., et al., “Clinical Prescribing of Allergic Rhinitis
`Medication in the Preschool andYoung School-Age Child, What are
`the Options?,” BioDrugs2001, vol. 15, No. 7, pp. 453-463, ADIS
`International Ltd.
`Gennaro, Alfonso R., ed., et al., Remington: The Science and Practice
`ofPharmacy, 2000, 20th edition, vol. 1, pp. 785, 830, 831 plus cover
`page and publication page, Lippincott Williams & Wilkins.
`Gilbert, Peter, et al., “Preservation of Pharmaceutical Products,”
`Encyclopedia of Pharmaceutical Technology, 2002, 2nd edition, vol.
`3, p. 2278 plus cover page and publication page, Marcel Dekker, Inc.
`Hodges, N. A., et al., “Preservative Efficacy Tests in Formulated
`Nasal Products: Reproducibility and Factors Affecting Preservative
`Activity,” J. Pharm. Pharmacol., 1996, vol. 48, pp. 1237-1242.
`Howarth, P. H., “A comparison ofthe anti-inflammatory properties of
`intranasal corticosteroids and antihistamines in allergic rhinitis,”
`Allergy 2000, vol. 62, pp. 6-11, Munksgaard 2000.
`Juniper, E F., et al., “Comparison of beclomethasone dipropionate
`aqueous nasal spray, astemizone, and the combination in the prophy-
`lactic treatment of ragweed pollen-induced rhinoconjunctivitis,”
`Journal ofAllergy and Clinical Immunology, Mar. 1989, vol. 83, No.
`3, Cover page, Publications page, pp. 627-633, American Academy
`of Allergy and Immunology, CV. Mosby Co.
`McNeely, Wendy, et al., “Intranasal Azelastine: A Review of its
`Efficacy in the Management of Allergic Rhinitis,” Drugs, 1998, vol.
`56, No. 1, pp. 91-114.
`Meltzer, Eli O., “Allergic rhinitis: Managing the pediatric spectrum,”
`Allergy and Asthma Proceedings, Jan-Feb. 2006, vol. 27, No. 1, pp.
`2-8, Oceanside Publications, Inc., USA.
`Nielsen, Lars P, “Comparison of Intranasal Corticosteroids andAnti-
`histamines in Allergic Rhinitis, A Review ofRandomized, Controlled
`Trials,”Am. J. Respir Med. 2003, vol. 2, No. 1, Cover page, publish-
`ing page, pp. 55-65., ADIS International Limited.
`Nielsen, Lars Peter, et al., “Intranasal Corticosteroids for Allergic
`Rhinitis, Superior Relier,” Drugs 2001, vol. 61, No. 11, pp. 1563-
`1579, ADIS International Ltd.
`Office Action dated Feb. 16, 2011, (22 pages), U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Office Action (Final) dated Feb. 18, 2011 (23 pages), U.S. Appl. No.
`12/508,388, filed Jul. 23, 2009.
`Pre-Grant Opposition, Indian Patent Application 2092/KOLNP/2007
`dated Jun. 8, 2007, 183 pages.
`
`Prescribing Information for Astepro®, Nov. 2010, 20 pages, Meda
`Pharmaceuticals Inc., Somerset, NJ, US.
`Prescribing Information for Rhinocort AquaTM, Dec. 2010, 32 pages,
`AstraZeneca LP, Wilmington, DE, US.
`“Azelastine,” STN Registry No. 58581-89-8, STN Registry File,
`Retrieved Nov. 23, 2010, p. 1.
`“Fluticasone Furoate,” STN Registry No. 397864-44-7, STN Regis-
`try File, Retrieved Nov. 23, 2010, p. 1.
`Astelin (azelastine hydrochloride) Nasal Spray, MedPointe Pharma-
`ceuticals, 2006, US Physicians Desk Reference, pp. 1876-1877.
`Veramyst (fluticasone furoate) Nasal Spray, Glaxo SmithKline, 2007,
`Summary Sheet, pp. 1-20.
`Astepro (azelastine HCI) Nasal Spray 0.15%, Meda Pharmaceuticals
`Inc., 2009, Press Release, pp. 1-4.
`Aigbirhio, Franklin I., et al., “Automated radiosynthesis of no-car-
`rier-added
`[S-fluoromethyl-18F]Fluticasone
`propionate
`as
`a
`radiotracer for lung deposition studies with PET,” Journal of Labelled
`Compounds and Radiopharmaceuticals, vol. 39, No. 7, 1997, pp.
`569-584.
`Austin, et al., “Mometasone furoate is a less specific glucocorticoid
`than fluticasone propionate,” Eur. Respir. J., 2002, vol. 20, pp. 1386-
`1392.
`Banov, et al., “Once daily intranasal fluticasone propionate is effec-
`tive for perennial allergic rhinitis,” Annals of Allergy, 1994, vol. 73,
`pp. 240-246.
`Barnes, Peter J., “Chronic obstructive pulmonary disease: new
`opportunities for drug development,” Trends in Pharmacological Sci-
`ences, vol. 19, No. 10, 1998, pp. 415-423.
`Barnes, Peter J., “Novel approaches and targets for treatment of
`chronic obstructive pulmonary disease,” American Journal of Respi-
`ratory and Critical Care Medicine, vol. 160, 1999, pp. S72-S79.
`Barnes, Peter J., “Efficacy of inhaled corticosteroids in asthma,” The
`Journal ofAllergy and Clinical Immunology, vol. 102, No. 4, 1998,
`pp. 531-538, 1998.
`BaumgaIten, C., et al., “Initial treatment of symptomatic mild to
`moderate bronchial
`asthma with the
`salmeterol/fluticasone
`propionate (50/250ug) combination product (SAS 40023),” Euro-
`pean Journal of Medical Research, 2002, vol. 7, pp. 1-7.
`Berstein, et al., “Treatment with intranasal fluticasone propionate
`significantly improves ocular symptons in patients with seasonal
`allergic rhinitis,” Clin. Exp. Allergy, 2004, vol. 34, pp. 952-957.
`Bowler, Simon, “Long acting beta agonists,” Australian Family Phy-
`sician, vol. 27, No. 12, 1998, pp. 1115, 1117-1118, plus cover.
`Brooks, et al., “Spectrum of seasonal allergic rhinitis symptom relief
`with topical corticoid and oral antihistamine given singly or in com-
`bination,” American Journal of Rhinology, 1996, vol. 10, No. 3, pp.
`193-199.
`Bryson, et al., “Intranasal fluticasone propionate: a review of its
`pharmacodynamic and pharmacokinetic properties, and therapeutic
`potential in allergic rhinitis,” Drugs, 1992, vol. 43, No. 5, pp. 760-
`775.
`Busse, William, et al., “Steroid-sparing effects of fluticasone
`propionate 100ug and salmeterol 50 ug administered twice daily in a
`single product in patients previously controlled with fluticasone
`propionate 250 ug administered twice daily,” J. Allergy Clin.
`Immunol., vol. 111, No. 1, Jan. 2003, pp. 57-65.
`CAS Registry No. 102113-40-6, 2004.
`CAS Registry No. 90566-53-3, “Fluticasone,” Nov. 16, 1984.
`Chapman, et al., “Anti-inflammatory activity of inhaled mometasone
`furoate in allergic mice,” Arzneimettelforschung (“Drug Research”),
`1998, vol. 48, No. 4, pp. 384-391.
`fluticasone
`Daley-Yates,
`et
`al.,
`“Systemic bioavailability of
`propionate administered as nasal drops and aqueous nasal spray
`formulations,” Br. J. Clin. Pharmocol., 2001, vol. 51, pp. 103-105.
`Derby, et al., “Risk of cataract among users of intranasal
`corticosteroids,” J. Allergy Clin. Immunol., 2000, vol. 105, No. 5, pp.
`912-916.
`Dewester, et al., “The efficacy of intranasal fluticasone propionate in
`relief of ocular symptoms associated with seasonal rhinitis,” Allergy
`and Asthma Proc., 2003, vol. 24, No. 5, pp. 331-337.
`Dictionary of Organic Compounds, 6th Ed., vol. 1, p. 3234 plus cover
`and publishing pages, definition of “fluticasone,” Chapman & Hall,
`1996.
`
`000004
`
`000004
`
`

`

`US 8,304,405 B2
`
`Page5
`
`Dolovich, et al., “Multicenter trial of fluticasone propionate aqueous
`nasal spray in ragweed allergic rhinitis,” Annals ofAllergy, 1994, vol.
`73, No. 2, pp. 147-153.
`Fowler, Stephen J., et al., “Step-down therapy with low-dose
`fluticasone-salmeterol
`combination
`or
`medium-dose
`hydrofluoroalkane 134a-beclomethasone alone,” J. Allergy Clin.
`Immunol., vol. 109, No. 6, Jun. 2002, pp. 929-935.
`Garner, R. C., et al., “A validation study comparing accelerator MS
`and liquid scintillation counting for analysis of 14C-labelled drugs in
`plasma, urine and faecal extracts,” Journal of Pharmaceutical and
`Biomedical Analysis, vol. 24, 2000, pp. 197-209.
`Gawchik, et al., “Comparison of intranasal triamcinolone acetonide
`with oral loratadine in the treatment of seasonal ragweed-induced
`allergic rhinitis,” Am. J. Man. Care, 1997, vol. 3, No. 7, pp. 1052-
`1058.
`Harding, “The human pharmacology offluticasone propionate,” Res-
`piratory Medicine, 1990, vol. 84, Suppl. A, pp. 25-29.
`Howland, “Fluticasone propionate:
`topical or systemic effects?”
`Clinical and Experimental Allergy, 1996, vol. 26, Suppl. 3, pp. 18-22.
`Isogai, et al., “Binding affinities of mometasone furoate and related
`compounds including its metabolites for the glucocorticoid receptor
`ofrat skin tissue,” J. Steroid Biochem. Mol. Biol., 1993, vol. 44, pp.
`141-145.
`Johansson, Gunnar, et al., “Comparison of salmeterol/fluticasone
`propionate combination with budesonide in patients with mild-to-
`moderate asthma,” Clin. Drug Invest., vol. 21, No. 9, 2001, pp.
`633-642, 11 pages,Adis International Limited.
`Juniper, Elizabeth F., et al., “Impact of inhaled salmeterol/fluticasone
`propionate combination product versus budesonide on the health-
`related quality of life of patients with asthma,” Am. J. Respir. Med.,
`vol. 1, No. 6, 2002, pp. 435-440.
`Kenley, Ricth A., et al., “An automated, column-switching HPLC
`method for analyzing active and excipient materials in both cream
`and ointment formulations,” Drug Development and Industrial Phar-
`macy, vol. 11 (9 & 10), 1985, pp. 1781-1796.
`Kertesz, Denis J., et al., “Thiol esters from steroid 17B-carboxylic
`acids: carboxylate activation and internal participation by 17
`ot-acylates,” J. Org. Chem., vol. 51, 1986, 14 pages.
`Knobil, K., et al., “Adding salmeterol is more effective than increas-
`ing the dose of fluticasone for patients with asthma who are symp-
`tomatic on low dose fluticasone,” European Respiratory Review,
`Copenhagen, DK, vol. 12, Suppl. 29, Dec. 1998, pp. 19S-20S plus
`cover page.
`Kooreman, et al., “The synthesis of 17-esters of corticosteroids pro-
`tection of 1 1 B-hydroxyl of the trimethylsilyl group,” Synthetic Com-
`munications, vol. 1, No. 2, pp. 81-87, 1971.
`Laforce, et al., “Fluticasone propionate: an effective alternative treat-
`ment for seasonal allergic rhinitis in adults and adolescents,” J. Fam.
`Pract., 1994, vol. 38, No. 2, pp. 145-152.
`new capillary
`a
`of
`Lane,
`S.
`J.,
`et
`al.,
`“Evaluation
`electrochromatography/mass spectrometry interface using short col-
`umns and high field strengths for rapid and efficient analyses,” Rapid
`Communications in Mass Spectrometry, vol. 10, 1996, pp. 733-736.
`Lewis, Sarah A., et al., “Association of specific allergen sensitization
`with socioeconomic factors and allergic disease in a population of
`Boston women,” J. Allergy Clin. Immunol., vol. 107, No. 4, Apr.
`2001, pp. 615-622.
`Li, et al., “Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under
`phase transfer catalysis,” Synthetic Communications, vol. 32, No. 20,
`pp. 3081-3086, 2002.
`Linder, “Symptom scores as measurements of the severity of
`rhinitis,” Clinical Allergy, 1988, vol. 18, pp. 29-37.
`Lumry, William R., “A review of the preclinical and clinical data of
`newer intranasal steroids in the treatment ofallergic rhinitis,” Allergy
`Clin. Immunol., Oct. 1999, 104 (4 Pt 1), pp. S150-S158 plus one
`correction page.
`Lutsky, et al., “A novel class of potent topical antiinflammatory
`agents: 17-benzolyated, 7a-halogeno substituted corticosteroids,”
`Arzneimettelforschung (“Drug Research”), 1978, vol. 29, No. 11, pp.
`1662-1667.
`Lyseng-Williamson, Katherine A., et al., “Inhaled salmeterol/
`fluticasone propionate combination in chronic obstructive pulmo-
`nary disease,”Am. J. Respir. Med., vol. 1, No.4, 2002, pp. 273-282.
`
`
`
`VIahoney, Janette M., et al., “Drug effects on the neovascularization
`response to silver nitrate cauterization ofthe rat cornea,” Current Eye
`Research, vol. 4, No. 5, 1985, pp. 531-535.
`VIeltzer, et al., “Onset of therapeutic effect of fluticasone propionate
`aqueous nasal spray,” Ann. Allergy Asthma Immunol., 2001, vol. 86,
`V0. 3, pp. 286-291.
`VIillard, Jeffrey W., et al., “Solubilization by cosolvents establishing
`useful constants
`for
`the log-linear model,” Int’l
`Journal of
`Pharmeceutics, vol. 245, 2002, pp. 153-166.
`VIistry, Nisha, et al., “Characterisation of impurities in bulk drug
`batches of fluticasone propionate using directly coupled HPLC-
`\IMR spectroscopy and HPLC-MS,” Journal of Pharmaceutical and
`Biomedical Analysis, vol. 16, 1997, pp. 697-705.
`VIistry, Nisha, et al., “Impurity profiling in bulk pharmaceutical
`batches using 19F NMR spectroscopy and distinction between
`monomeric and dimeric impurities by NMR-based diffusion mea-
`surements,” Journal ofPharmaceutical and Biomedical Analysis, vol.
`19, 1999, pp. 511-517.
`/
`pharmacokinetic
`al., Handbook of
`Mollmann, H.,
`et
`pharmacodynamic
`correlation, Chapter
`14, Pharmacokinetic-
`Pharmacodynamic Correlations of Corticosteroids, 323-336 plus
`cover and publishing pages, CRC Press, 1995.
`Moreno-Vargas, et al., “Synthesis and gylcosidase inhibitory activi-
`ties of 5-(1',4'-dideoxy-1‘,4'-imino-D-erythrosyl)-2-methyl-3-furoic
`acid (:5-[(3S,4R)-3,4-dihydroxypyrrolidin-2-yl]-2methylfuran-3-
`carboxylic acid) derivatives: new leads as
`selective alpha-L-
`fucosidase and beta-galactosidase inhibitors,” Helvetica Chimica
`Acta, vol. 86, pp. 1894-1913, 2003.
`Naedele-Risha, R., et al., “Dual components of optimal asthma
`therapy: scientific and clinical rationale for the use of long acting
`beta-agonists with inhaled corticosteroids,” The Journal of the
`American Osteopathic Association, vol. 101, No. 9, Sep. 2001, pp.
`526-533.
`Nathan, et al., “A once daily fluticasone proprionate aqueous nasal
`spray is an effective treatment for seasonal allergic rhinitis,” Annals
`ofAllergy, 1991, vol. 67, pp. 332-338.
`Nelson, Harold, S., et al., Fluticasone propionate-salmeterol combi-
`nation provides more effective asthma control than low-do se inhaled
`corticosteroid plus montelukast, J. Allergy Clin. Immunol., vol. 106,
`No. 6, Dec. 2000, pp. 1088-1095.
`O’Conner, B. J., “Combination therapy,” Pulmonary Pharmacology
`and Therapeutics, vol. 11, No. 5/6, 1998, pp. 397-399.
`Ong, John T. H., et al., “Micellar solubilization oftimobesone acetate
`in aqueous and aqueous propylene glycol solutions of nonionic
`surfactants,” Pharmaceutical Research, vol. 5, No. 11, 1988, pp.
`704-708.
`Ong, John T. H., et al., “Intrinsic potencies of novel thiol ester
`corticosteroids RS-85095 and RS-21314 as
`compared with
`clobetasol 17-propionate and fluocinonide,” Arch Dermatol, vol.
`125, Dec. 1989, pp. 1662-1665.
`Onrust, et al., “Mometasone furoate, a review of its intranasal use in
`allergic rhinitis,” Drugs, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol.
`21.
`Holgate, Stephen T., Difficult Asthma, 1999, cover page and publish-
`ing information.
`PCT/GB01/03495, International Preliminary Examination Report,
`date of completion of report: Aug. 30, 2002.
`Pettersson, Bertil, et al., “Re-evaluation of the classical mycoplasma
`lipophilum cluster (Weisburg, et al., 1989) and description of two
`new clusters in the hominis group based on 16S rDNA sequences,”
`Int’l Journal of Systematic & Evolutionary Microbiology, 2001, vol.
`51, pp. 633-643, IUMS, Great Britain.
`Phillips, G. H., et al., “Synthesis and structure activity relationships
`in a series of anti-inflammatory corticosteroid analogues, halomethyl
`androstane-17B-carbothioates and717B-carboselenoates,” Journal
`of Medicinal Chemistry, 1994, vol. 37, pp. 3717-3729.
`Popper, T. L., et al., “Structure-activity relationships of a series of
`novel topical corticosteroids,” Journal of Steroid Biochemistry, 1987,
`vol. 27, pp. 837-843, Pergamon Journals Ltd.
`Product Information Flonase (Flutic